  ---
 title: Tolvaptan - INICET Cheat Sheet
 markmap:
   colorFreezeLevel: 6
 ---

 ## Tolvaptan

 - **Mechanism of Action**
   - Selective Vasopressin V2 Receptor Antagonist
   - Inhibits ADH/Vasopressin binding
   - Increases free water excretion (Aquaresis)
   - Increases serum sodium
 - **Key Indications (High Yield)**
   - Euvolemic & Hypervolemic Hyponatremia
     - SIADH (Syndrome of Inappropriate ADH)
     - Heart Failure
     - Cirrhosis (less common now due to side effects/alternatives)
   - Autosomal Dominant Polycystic Kidney Disease (ADPKD)
     - Slows cyst growth & kidney function decline
 - **Contraindications**
   - Hypovolemic Hyponatremia
   - Inability to sense thirst or access water
   - **Risk of Osmotic Demyelination Syndrome (OSDS)** if rapid correction expected
   - Anuria
   - Concomitant use with strong CYP3A4 Inhibitors
   - Significant liver disease (for ADPKD indication, specific cautions)
 - **Side Effects**
   - **Common:** Thirst, Dry Mouth, Polyuria, Frequent Urination
   - Hypotension
   - Hyperglycemia
   - **Severe:**
     - **Osmotic Demyelination Syndrome (OSDS)** - Risk with rapid Na correction (>8-10 mEq/L in 24h)
     - Liver Injury (especially with high doses for ADPKD, requires monitoring)
 - **Monitoring**
   - **Frequent Serum Sodium** (especially in first 24-48 hours of initiation/dose titration for hyponatremia) - Crucial to prevent OSDS!
   - Fluid Intake/Output
   - Liver Function Tests (LFTs) - Required for ADPKD treatment due to hepatotoxicity risk
 - **INICET Buzzwords**
   - Aquaresis
   - V2 Receptor Antagonist
   - SIADH
   - ADPKD
   - Osmotic Demyelination Syndrome (ODS/OSDS)
   - Rapid Sodium Correction
   - Hyponatremia Treatment

 
 